

IN THE CLAIMS

Please amend the claims to read as follows:

1-28. (Canceled)

29. (Currently amended) A purified antibody that specifically binds to an epitope in an amino acid sequence selected from:

(a) the amino acid sequence of SEQ ID NO:17;

(b) a fragment of the amino acid sequence of SEQ ID NO:17 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine;

~~(b)~~ (c) the amino acid sequence of SEQ ID NO:19;

~~(e)~~ (d) a fragment of the amino acid sequence of SEQ ID NO:19 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine;

~~(d)~~ (e) the amino acid sequence of SEQ ID NO:21;

~~(e)~~ (f) a fragment of the amino acid sequence of SEQ ID NO:21 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidyl

choline;

~~(f)~~ (g) the amino acid sequence of SEQ ID NO:23; and

~~(g)~~ (h) a fragment of the amino acid sequence of SEQ ID NO:23 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine.

30. (Previously presented) The antibody of claim 29, wherein the epitope is

in the amino acid sequence of SEQ ID NO:17.

31. (Previously presented) The antibody of claim 29, wherein the epitope is in the amino acid sequence of SEQ ID NO:19.

32. (Previously presented) The antibody of claim 29, wherein the epitope is in a fragment of the amino acid sequence of SEQ ID NO: 19 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine.

33. (Previously presented) The antibody of claim 29, wherein the epitope is in the amino acid sequence of SEQ ID NO:21.

34. (Previously presented) The antibody of claim 29, wherein the epitope is in a fragment of the amino acid sequence of SEQ ID NO:21 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidyl choline

35. (Previously presented) The antibody of claim 29, wherein the epitope is in the amino acid sequence of SEQ ID NO:23.

36. (Previously presented) The antibody of claim 29, wherein the epitope is in a fragment of the amino acid sequence of SEQ ID NO:23 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine

37. (Previously presented) The antibody of claim 29, wherein the antibody is a monoclonal antibody.

38. (Previously presented) The antibody of claim 29, wherein the antibody is a polyclonal antibody.

39. (Previously presented) A composition comprising the antibody of claim 29 and a pharmaceutically acceptable carrier.

40. (Currently amended) A purified antibody that specifically binds a polypeptide selected from:

(a) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO:

16;

(a)(b) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO:

18;

(b)(c) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO:

20; and

(e)(d) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of SEQ ID NO:

22[.];

(e) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 69948; and

(f) a polypeptide encoded by a polynucleotide, wherein the polypeptide has activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine, and wherein the polynucleotide hybridizes at 65°C in 4x SSC to the complement of the nucleic acid sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 69949.

41. (Previously presented) The antibody of claim 40, wherein the antibody is a monoclonal antibody.

42. (Previously presented) The antibody of claim 40, wherein the antibody is a polyclonal antibody.

43. (Previously presented) A composition comprising the antibody of claim 40 and a pharmaceutically acceptable carrier.

44. (Currently amended) A purified antibody that specifically binds to the polypeptide encoded by a nucleic acid molecule selected from SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, the DNA insert of the plasmid deposited with ATCC as Accession Number 69948, the DNA insert of the plasmid deposited with ATCC as Accession Number 69949, and a complement thereof a nucleotide sequence that hybridizes at 65°C in 4X SSC to the full length of the complement of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, the DNA insert of the

plasmid deposited with ATCC as Accession Number 69948, or the DNA insert of the
plasmid deposited with ATCC as Accession Number 69949.

45. (Previously presented) A composition comprising the antibody of claim 44 and a pharmaceutically acceptable carrier.

46. (Previously presented) The antibody of claim 44, wherein the antibody is a monoclonal antibody.

47. (Previously presented) The antibody of claim 44, wherein the antibody is a polyclonal antibody.

48. (Withdrawn) An antibody that binds to a polypeptide encoded by a polynucleotide selected from:

(a) a first polynucleotide having the nucleotide sequence of SEQ ID NO: 1;

(b) a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 2;

(c) a third polynucleotide that hybridizes at 65°C in 4x SSC to the complement of the first or second polynucleotide, wherein the third polynucleotide encodes a polypeptide having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl phosphatidylcholine;

49. (Withdrawn) The antibody of claim 48, wherein the antibody is a monoclonal antibody.

50. (Withdrawn) The antibody of claim 48, wherein the antibody is a polyclonal antibody.

51. (Withdrawn) A composition comprising the antibody of claim 48 and a pharmaceutically acceptable carrier.

52. (Withdrawn) An antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2.

53. (Withdrawn) The antibody of claim 52, wherein the antibody is a monoclonal antibody.

54. (Withdrawn) The antibody of claim 52, wherein the antibody is a polyclonal antibody.

55. (Withdrawn) A composition comprising the antibody of claim 52 and a pharmaceutically acceptable carrier.

56. (New) The antibody of claim 29, wherein the epitope is in a fragment of the amino acid sequence of SEQ ID NO: 17 having activity in a mixed micelle assay with 1-palmitoyl-2-[¹⁴C]-arachidonyl-phosphatidylcholine.